INTRODUCTION
============

Hepatocellular carcinoma (HCC) is a peculiar neoplasm with characteristics that differ from other tumor types, the major difference being that it most often occurs in association with chronic liver disease.

Gene expression studies in tumorous and surrounding non-tumorous liver tissues have identified molecular profiles associated with tumor differentiation, recurrence, vascular invasion, and patient survival [@b1-cln_71p639]-[@b3-cln_71p639]. Angiogenesis activation pathways have been reported to play a role in HCC carcinogenesis [@b4-cln_71p639].

Vascular endothelial growth factor (VEGF) is one of the most important factors involved in tumoral angiogenesis. VEGF is a potent endothelial cell mitogen that induces the formation of new vessels and increases vascular permeability [@b5-cln_71p639]. In addition, VEGF expression in HCC has been correlated with tumor aggressiveness (capsular infiltration, vascular invasion and intrahepatic metastasis) [@b6-cln_71p639]-[@b8-cln_71p639] and microvascular density (MVD) [@b9-cln_71p639].

Immunohistochemical evaluation of MVD using antibodies against CD34, CD31, and CD105 has been performed to evaluate tumor angiogenesis. However, CD105 is a more specific marker for tumor angiogenesis than CD34 or CD31, which are pan-endothelial markers [@b10-cln_71p639].

Cyclooxygenase-2 (COX-2) participates in carcinogenesis via different mechanisms, such as by promoting angiogenesis and cellular proliferation and inhibiting apoptosis [@b11-cln_71p639]. High COX-2 expression has been demonstrated in non-HCC tumors, including gastrointestinal cancers [@b12-cln_71p639]-[@b14-cln_71p639]. In addition, COX-2 [@b15-cln_71p639],[@b17-cln_71p639], VEGF [@b6-cln_71p639],[@b16-cln_71p639] and CD105 [@b17-cln_71p639] are expressed in chronic liver diseases.

Considering that VEGF, COX-2, and CD105 are involved in tumoral angiogenesis and that HCC is a highly vascularized tumor that occurs mainly in chronically diseased livers exhibiting neoangiogenesis, we investigated immunohistochemical expression patterns of VEGF, COX-2, and MVD-CD105 in HCC and surrounding cirrhotic liver tissues. Furthermore, we evaluated the putative association of these markers with HCC pathological features, including tumor size, differentiation grade, and microvascular invasion status.

MATERIAL AND METHODS
====================

Patients and pathology findings
-------------------------------

We studied 52 HCC and 48 surrounding cirrhotic liver tissue samples obtained during orthotopic liver transplantation or partial hepatectomy procedures performed in 38 male and 14 female adult patients with cirrhosis (aged 18--69 years). Forty-three patients had hepatitis C virus infection in isolation or in association with other etiologies. Twenty-six tumors were ≤2 cm in diameter, and 26 were \>2 cm in diameter. According to grading, 40 of the 52 HCC tumors were well differentiated (grade I and II), 7 were moderately differentiated (grade III), and 5 were poorly differentiated (grade IV). In cases with more than one histological grade, the highest grade was considered. Microvascular invasion was present in 23 (44.2%) tumors.

This study was approved by the local ethics committee of our institution (N° 163/11)

Immunohistochemistry
--------------------

Paraffin-embedded tissues were sectioned. The sections (5 µm) were deparaffinized in xylene, dehydrated and rehydrated in ethanol, and subjected to steamer antigen retrieval. The sections were then processed using a Novocastra Novolink polymer detection system (Leica Biosystems Newcastle Ltd, UK) with the following primary antibodies: mouse anti-human VEGF C-1 (sc-7269, 1:6000; Santa Cruz Biotechnology Inc, USA), mouse anti-human CD105 (Endoglin) (clone 4G11, 1:60; Leica Biosystems Newcastle Ltd, UK), and rabbit anti-human COX-2 (clone SP21,SPB-M3212, 1:500; Spring Bioscience, USA). Negative controls lacked the primary antibody and were processed simultaneously.

Evaluation of immunohistochemical staining
------------------------------------------

VEGF and COX-2 immunostaining was scored semiquantitatively according to modification of a previous method [@b18-cln_71p639]. Briefly, positive immunostaining was assessed in tumor cells for the HCC samples or hepatocytes for the cirrhotic tissues. Staining intensity was scored as 0, negative; 1, weak; 2, moderate; or 3, strong. The degree of staining was scored based on the percentage of positive cells as follows: 0, 0--4.9%; 1, 5--25%; 2, 26--50%; 3, 51--75%; and 4, 76--100%. When there was any doubt in the score to be assigned, the highest score was chosen. The sum of the intensity and the degree of the staining scores was used to produce a final overall score as follows: 0--1, negative; 2--3, weak; 4--5, moderate; and 6--7, strong. Lastly, the final mean scores were evaluated for all tissues.

CD105-stained tissues were evaluated using computer-based quantitative analysis to assess MVD. For the analyses, 3 microscope fields showing the highest staining intensity (hot spots), such as blood vessels or endothelial cells, were examined using an Olympus microscope, model BX-40. All images were captured using an Olympus digital 3.3-megapixel camera attached to the microscope. The images were analyzed using the "color function" and area/density measurement function in Imagelab® software. The MVD-CD105 percentages were calculated over a fixed area of 216 μm for each field. The average of the 3 fields was recorded as the mean MVD score.

Statistical analysis
--------------------

Fisher's exact test or the *χ*^2^ test was used to compare categorical variables. The Mann-Whitney test or Spearman\'s rank (rs) correlation coefficient was used to compare continuous variables. Quantitative data are presented as the mean±standard deviation (SD). Statistical analyses were performed using SAS^®^ System software, version 6.11 (SAS Institute, Inc., Cary, North Carolina), and *p*\<0.05 was considered statistically significant. The statistical methods used in this study were reviewed by a biomedical statistician from the Division of Biostatistics at Clementino Fraga Filho Hospital.

RESULTS
=======

VEGF, COX-2, and MVD-CD105 expression in HCC samples and surrounding cirrhotic liver tissues
--------------------------------------------------------------------------------------------

Diffuse cytoplasmic VEGF expression was detected in all HCC and cirrhotic liver tissue samples. The mean VEGF score was slightly higher in the HCC tissues (4.83±1.35) compared with the cirrhotic tissues (4.38±1.28). There was a significant and direct association between VEGF expression in the HCC and cirrhotic tissues (*r~s~*=0.645, *p*=0.0001). COX-2 was expressed in all the cirrhotic liver samples but only in 78% of the HCC samples. The mean COX-2 score was higher in the cirrhotic tissues (4.85±1.38) compared with the HCC tissues (2.58±1.68), but there was no association between the two (*r~s~*=0.177, *p*=0.23). The mean MVD-CD105 values were lower in all HCC samples (11.2%) compared to cirrhotic tissues (16.9%). Although there was no significant correlation in MVD-CD105 percentages between the HCC and cirrhotic tissues, an inverse relationship was apparent (r~s~=-0.78, *p*=0.67). Examples of immunohistochemical staining in the HCC and cirrhotic tissues are shown in [Figure 1](#f1-cln_71p639){ref-type="fig"}.

Correlation of VEGF, COX-2, and MVD-CD105 with pathological features
--------------------------------------------------------------------

In the HCC cases, cytoplasmic VEGF expression in tumor cells was mostly moderate or strong (48.32% or 36.53%, respectively). Although expression intensity did not significantly differ in relation to tumor size (*p*=0.37), a moderate expression pattern predominated in smaller tumors (\<2 cm). There was no association between VEGF expression and HCC differentiation grade or microvascular invasion status, although moderate-intensity staining predominated in well-differentiated HCC ([Table 1](#t1-cln_71p639){ref-type="table"}). COX-2 expression was significantly associated with HCC differentiation grade (*p*=0.003), but not with size or microvascular invasion status ([Table 2](#t2-cln_71p639){ref-type="table"}). Likewise, the mean MVD-CD105 values were not associated with microvascular invasion status or tumor size in the HCC tissues, although the mean MVD-CD105 expression tended to be higher in smaller tumors (≤2 cm). However, MVD-CD105 expression was significantly higher in well-differentiated HCC tissues compared with poorly and moderately differentiated tissues (*p*=0.05) ([Table 3](#t3-cln_71p639){ref-type="table"}). There were no correlations between the mean VEGF, COX-2, or MVD-105 scores. However, inverse relationships were noted between the MVD-105 and VEGF scores (*r~s~*=-0.13, *p*=0.33) and the MVD-105 and COX-2 scores (*r~s~*=-0.15, *p*=0.29).

DISCUSSION
==========

VEGF acts as a key mediator of tumoral angiogenesis by increasing vascular permeability and promoting endothelial proliferation and migration [@b19-cln_71p639]. In the liver carcinogenesis, the VEGF expression increases gradually from its early stages [@b20-cln_71p639]. VEGF expression has been associated with patient prognosis in terms of overall survival and recurrence [@b21-cln_71p639], including after liver transplantation when observed in adjacent cirrhotic tissue [@b22-cln_71p639].

Our data showed that mean VEGF expression was slightly higher in HCC tissues compared with surrounding cirrhotic tissues, and there was a positive correlation between them. This suggested a close relationship between VEGF expression and carcinogenesis, which was congruent with previous observations [@b23-cln_71p639] and reinforces the importance of VEGF in HCC. Conversely, other studies have reported the predominance of VEGF in non-tumorous cirrhotic tissue [@b6-cln_71p639],[@b24-cln_71p639], but not in cirrhotic nodules distant from HCC [@b25-cln_71p639]. It is possible that we observed higher VEGF scores in HCC because we evaluated smaller tumors (≤2 cm) than those examined in other studies (5 cm). In the present study, all HCC and surrounding cirrhotic tissues expressed VEGF, which is in agreement with the findings of Imura et al. [@b26-cln_71p639], who observed VEGF expression in all HCC tissues. In contrast, in another study, VEGF positivity was reported in 66.7% of HCC samples and 79.4% of cirrhotic tissues [@b6-cln_71p639]. Disagreements between studies using immunohistochemical profiling might arise because of the different methods employed to score staining. However, in accordance with the same study [@b6-cln_71p639], we did not observe any significant associations between VEGF expression and differentiation grade, microvascular invasion status, or tumor size. This might suggest that VEGF-stimulated angiogenesis does not change significantly during HCC progression.

In HCC, vascularization can result in the development of new vessels by neoangiogenesis or from the preexisting sinusoidal network by angiogenesis [@b27-cln_71p639]. MVD, assessed by CD105 immunostaining, has been suggested as a quantitative measure of tumoral angiogenesis and has been reported as a prognostic indicator of outcome in malignant tumors, including HCC [@b7-cln_71p639]. In the present study, MVD-CD105 expression was slightly higher in smaller tumors, although it was not significantly different compared to that in larger tumors (\>2 cm). Similarly, MVD-CD105 expression was not associated with microvascular invasion status, but it was associated with well-differentiated HCC. Additionally, MVD-CD105 expression tended to decrease as grade increased. Ho et al. [@b28-cln_71p639] found a correlation between low MVD-CD105 expression and a more aggressive tumor type, as indicated by a large size and microvascular invasion. It is possible that the lack of association between MVD-CD105 expression and microvascular invasion in the present study resulted from the smaller average size of the advanced lesions that were examined (4.8 cm); in contrast to our current work, Ho et al. compared tumors that were ≤5 cm in diameter with those \>5 cm in diameter. Such findings in combination with our previous observations [@b29-cln_71p639] suggest that MVD-CD105 expression decreases during carcinogenesis and tumor progression.

COX-2 overexpression has been documented in patients with HCC with concomitant hepatitis virus infection [@b14-cln_71p639]. Immunohistochemical staining revealed COX-2 expression in the majority of HCC tissues and all cirrhotic tissues evaluated in the present study, which was concordant with previous studies [@b15-cln_71p639] [@b17-cln_71p639]. Moreover, previous studies have indicated that COX-2 RNA expression is higher in adjacent liver tissues than in HCC tissues [@b30-cln_71p639]. In contrast, other reports have found 100% of HCC samples showing COX-2 positivity [@b31-cln_71p639],[@b32-cln_71p639]. Hepatitis C virus infection can promote COX-2 expression [@b33-cln_71p639], which might explain why all the non-tumorous tissues in the present study were COX-2-positive. We found that COX-2 expression was associated with HCC differentiation grade, but not with microvascular invasion status or tumor size. COX-2 expression was higher in well-differentiated HCC, suggesting that it may be involved in the early stages of carcinogenesis [@b31-cln_71p639],[@b32-cln_71p639]. Cervello et al. [@b32-cln_71p639] suggested that COX-2 overexpression in tumor progression might cause growth disadvantages in certain cells. Regarding tumor size, Koga et al. [@b31-cln_71p639] observed a predominance of COX-2 in small HCC tumors compared with large tumors. Epigenetic studies have implied that reduced COX-2 expression is associated with poor prognosis in patients with HCC [@b30-cln_71p639].

In conclusion, this study shows that VEGF, COX-2, and MVD-CD105 expression were higher in cirrhotic liver tissues compared with HCC tissues, which suggests that these proteins play important roles in liver carcinogenesis. In addition, both COX-2 and MVD-CD105 expression appeared to play roles in HCC differentiation.
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###### 

VEGF expression patterns according to morphological features.

  Variables              n    VEGF expression (%)   *p*                  
  ---------------------- ---- --------------------- ------ ------ ------ ------
  **Size**                                                               0.37
      **≤2.0 cm**        26   \-                    15.4   57.7   26.9   
      **\>2.0 cm**       26   \-                    15.4   38.5   46.1   
  **Differentiation**                                                    0.91
      **Grade I/II**     40   \-                    15.0   50.0   35.0   
      **Grade III/IV**   12   \-                    16.7   41.7   41.6   
  **MI invasion**                                                        0.53
      **Present**        23   \-                    17.4   39.1   43.5   
      **Absent**         29   \-                    13.8   55.2   31.0   

N -- negative; Mod -- moderate; MI -- microvascular

###### 

Cox-2 expression patterns according to morphological features.

  Variables              n    COX-2 expression (%)   *p*                 
  ---------------------- ---- ---------------------- ------ ------ ----- -------
  **Size**                                                               0.12
      **≤2.0 cm**        26   15.4                   57.6   23.1   3.9   
      **\>2.0 cm**       26   26.9                   30.8   42.3   \-    
  **Differentiation**                                                    0.003
      **Grade I/II**     40   10.0                   52.5   35.0   2.5   
      **Grade III/IV**   12   58.3                   16.7   25.0   \-    
  **MI invasion**                                                        0.84
      **Present**        23   26.1                   39.1   34.8   \-    
      **Absent**         29   17.2                   48.3   31.0   3.5   

N -- negative; Mod -- moderate; MI -- microvascular

###### 

Microvascular density of CD105 according to morphological features.

  Variables              n      MDV-CD105   *p*    
  ---------------------- ---- ------------- ------ ------
  **Size**                                         0.1
      **≤2.0 cm**        26   12.5          5.2    
      **\>2.0 cm**       26   9.92          4.43   
  **Differentiation**                              0.05
      **Grade I/II**     40   11.9          5.0    
      **Grade III/IV**   12   8.87          4.49   
  **MI invasion**                                  0.12
      **Present**        23   9.8           3.9    
      **Absent**         29   12.31         5.48   

N -- negative; SD -- standard deviation; MI -- microvascular; MDV -- microvascular density
